ACC.19: 3 Studies in Cardioprotection

News
Slideshow

Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA.

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
Guideline Topline: 2025 AHA/ACC Hypertension / image credit Dan Jones, MD, University of Mississippi Foundation

AHA/ACC Release Revised Hypertension Clinical Practice Guidelines to Reduce CVD Risk

Grace Halsey
August 19th 2025
Article
The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Sydney Jennings
August 19th 2025
Podcast
Noninvasive Primary Care Screening Identifies Elevated LVEDP in Nearly 40% of High-Risk Patients

Noninvasive Primary Care Screening Identifies Elevated LVEDP in Nearly 40% of High-Risk Patients

Sydney Jennings
August 19th 2025
Article
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 19th 2025
Podcast
FDA Approves Finerenone for Treatment of Heart Failure With LVEF ≥40%: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves Finerenone for Treatment of Heart Failure With LVEF ≥40%: Daily Dose

Sydney Jennings
August 19th 2025
Article
Cardiovascular Health

Only 1 in 5 Women Meet Heart Health Targets at Midlife, and These 4 Factors Matter Most

Grace Halsey
August 19th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.